MedTrace Logo

NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery

NCT07382479 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 485

Last updated 2026-02-05

No results posted yet for this study

Summary

A prospective, international, multi-center, interventional trial of advanced epithelial ovarian cancer patients offered three cycles of neoadjuvant chemotherapy (NACT) and triaged with KELIM score. Patients with favorable score will undergo interval debulking surgery (IDS) followed by another 3 cycles, while those with unfavorable score will undergo another 3 cycles of NACT followed by delayed interval debulking surgery (DIDS).

Conditions

Interventions

PROCEDURE

3 cycles of NACT with unfavorable KELIM score will receive 3 more cycles of NACT followed by DIDS

3 cycles of NACT with unfavorable KELIM score will receive 3 more cycles of NACT followed by DIDS

PROCEDURE

3 cycles of NACT with favorable KELIM score will undergo IDS followed by 3 cycles of NACT

3 cycles of NACT with favorable KELIM score will undergo IDS followed by 3 cycles of NACT

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Dimitrios Tsolakidis, Dr.Prof. · Artistotle University of Thessaloniki

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2031-04-01
Completion
2034-04-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07382479 on ClinicalTrials.gov